drugset / Trial / NCT04303988
A Phase II Study of Triple-negative Breast Cancer Brain Metastases.
NaSingle-groupOpen-labelTreatment
Summary
Study to assess the effectiveness and safety of SHR 1316, bevacizumab combined with cisplatin/carboplatin for treatment of triple-negative breast cancer brain metastases.
Timeline
- Start
- 2020-03-30
- Primary completion
- 2024-12-30
- Completion
- 2025-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | — | — |
| Subject | Bevacizumab | Monoclonal antibody | — | — |
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Cisplatin | Other / unclassified | — | — |